valtropin
Commercial- Indications
- Growth hormone deficiency, Turner's syndrome
Company intelligence / Profile preview
BioPartners develops and commercializes innovative formulations and novel delivery systems for first-generation biopharmaceuticals in endocrinology, multiple sclerosis, and virology. They are advancing a prolonged-release recombinant human growth hormone that reduces injection frequency from daily to weekly—a significant advance in hGH therapy. The company has an international presence with headquarters in Switzerland and an affiliate in Germany, collaborating widely for product development and distribution.[2] Clinical results are not detailed but the lead program was described as nearing regulatory submission.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BioPartners.